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Background: Interferon (IFN) therapy can cause significant side effects in chronic hepatitis C (CHC) patients;
however, the health-related quality of life (HRQOL) of antiviral-treated CHC patients has not been established
in Taiwan. This study evaluated domains and the degree to which antiviral treatment affects the HRQOL in CHC
patients and identifies factors associated with variations between patients.
Methods: Health-related quality of life (HRQOL) was assessed using the Short Form-36 (SF-36) and the Chronic
Liver Disease Questionnaire (CLDQ) in 108 antiviral-treated CHC patients. Eight scales and two summary scales of
the SF-36 were compared with 256 age- and gender-matched population norms and 64 age- and gender-matched
CHC patients without antiviral therapy. Descriptive statistic measures, one-way ANOVA, and regression analysis were
used for data analysis.
Results: (1) CHC patients receiving antiviral treatment displayed significantly lower scores in six scales, the Physical
Component Summary (PCS), and the Mental Component Summary (MCS) of the SF-36, when compared to the
population norms and patients without antiviral therapy (p < 0.05). (2) The mean CLDQ score of antiviral-treated
patients was lower than that of patients without antiviral therapy, including subscales of ‘fatigue’, ‘systemic symptoms’,
and ‘role emotion’. (3) All SF-36 subscales significantly correlated with all CLDQ subscales, with the greatest correlation
coefficients shown between fatigue and vitality and mental health of SF-36. (4) Antiviral therapy had a greater negative
impact on females in the CLDQ, on all patients during treatment weeks 9–16 in the PCS and on patients with a
monthly income of less than NT$10,000 in the CLDQ, PCS, and MCS.
Conclusions: This study highlighted impairments in the quality of life of chronic hepatitis C patients treated with
IFN-based therapy. The significant factors associated with HRQOL include gender, income, and treatment duration. The
results of this study might provide nurses with a comprehensive understanding of HRQOL and its determining factors
in antiviral-treated CHC patients. The findings can serve as a useful reference for nursing personnel in developing
instructions for upgrading the care of CHC patients.
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Chronic hepatitis C (CHC) is one of the major causes of
liver cirrhosis and hepatocellular carcinoma (HCC). Pre-
vious research indicated the prevalence of anti-hepatitis
C virus (HCV) antibody positivity in Taiwan was 4.4%,
with the total number of HCV carriers in the general
population reaching approximately 420,000 [1]. It is
estimated that 85% of HCV-infected individuals will
progress to CHC [2]. Over time, approximately 35% of
patients with CHC will progress to cirrhosis and 20%
of patients will develop HCC [3,4].
Interferon (IFN) plus ribavirin therapy is the current
standard of care for antiviral treatment of CHC [5,6];
however, this treatment causes adverse events, including
fatigue, myalgia, influenza-like symptoms, alterations in
mood, the inability to concentrate, and changes in libido.
These events may have a negative effect on a patient’s
vitality, social interaction, and ability to perform work
and other activities, and may force a discontinuation of
therapy [7,8]. Although qualitative and quantitative study
methods have shown that IFN-based treatment for CHC
patients has a negative impact on health-related quality of
life (HRQOL) [9-11], studies of the impact of IFN-based
treatment on HRQOL in CHC patients are limited.
Generally, it is recommended that both generic and
disease-specific measures be used in HRQOL surveys or
trials. Generic measures provide comparisons between
general populations and patients with chronic conditions,
whereas disease-specific measures assess disease-specific
symptoms and are more sensitive to changes, including
small yet clinically significant changes. Disease-specific
measures can capture patients’ experiences throughout
the course of a disease and its treatment. The Short Form
36 Questionnaire (SF-36) is one tool commonly used as a
generic measure to assess HRQOL. It has gained popular-
ity as a means of evaluating outcomes in a wide variety of
patient groups and surveys. HRQOL measures specifically
developed in previous decades for chronic liver disease
include the Chronic Liver Disease Questionnaire (CLDQ)
and the Hepatitis Quality of Life Questionnaire (HQLQ).
The CLDQ is the most commonly used instrument and
has the advantage of being a short and feasible question-
naire [12]. On the contrary, the HQLQ is considered too
lengthy and lacking validity [13,14].
Studies of HRQOL of CHC patients undergoing treat-
ment have shown that antiviral treatment has an enormous
impact on HRQOL compared with untreated patients
[15-20]. Reports indicate that the HRQOL of untreated
CHC patients either resembles the general population [21]
or is lower than that of healthy individuals [20,22,23].
Two previous studies addressed the HRQOL in CHC
patients undergoing treatment in countries with a high
HCV prevalence such as Taiwan. One study used disease-
specific scales of the Hepatitis Quality of Life Questionnaire(HQLQ) [24], while the other applied the Taiwanese version
of the WHOOQOL-BREF [25]. Neither study evaluated the
HRQOL in CHC patients undergoing treatment using
disease-specific and generic measures simultaneously.
The present study used the SF-36 to determine the do-
mains in which antiviral treatment affects CHC patients
and the degree to which patients are affected compared
with Taiwanese population norms on 10 scales of the
SF-36. The study also aimed to identify determinants of
HRQOL as measured by SF-36 and CLDQ.
Materials and methods
This study used a cross-sectional design. Questionnaires
were used to interview antiviral-treated CHC patients at
outpatient clinics in one medical center in central Taiwan.
Patients were diagnosed with CHC if they had both
HCV antibody and HCV RNA positivity for more than
six months, elevated serum alanine aminotransferase
(ALT) levels, and diagnostic confirmation by experienced
hepatologists. One hundred and eight participants were
currently undergoing pegylated IFN plus ribavirin therapy,
while 84 participants were recruited for the non-treated
groups. To compare the HRQOL, 64 antiviral-treated
CHC patients were frequency-matched based on their
age and gender with 64 CHC patients without antiviral
therapy. Subjects were interviewed before filling out
questionnaires with the interviewer’s assistance during
outpatient clinic visits from July 1, 2010 to December
31, 2011. Patients’ baseline characteristics, including
age, gender, marital status, educational level, current
employment, monthly income, on-visit ALT levels, and
treatment duration were collected. The investigators
administered two questionnaires: the generic Short
Form 36 (SF-36) and the CLDQ. The SF-36 consists of
thirty-six items divided into eight scales that can be
combined into two summary scores: the mental component
summary (MCS) and the physical component summary
(PCS). The SF-36 scales are: 1) physical functioning (PF), 2)
role physical (RP), 3) bodily pain (BP) 4), general health
(GH), 5) vitality (VT), 6) social functioning (SF), 7) role
emotion (RE), and 8) mental health (MH). Scores for these
SF-36 scales range between 0 and 100, with higher scores
indicating a better HRQOL. The tool is well-established
as a valid measurement and is widely considered to yield
adequate data quality. The scales are derived from the
standard SF-36 scoring algorithms [26].
The Chinese (Taiwan) SF-36 Health Survey has been
translated, validated, and normalized for the general
Chinese population in Taiwan. Previous reports on the
norms and internal consistency of the Taiwanese version
of the SF-36 indicate that the reliability coefficient of
internal consistency for the total scale was 0.86 [27,28].
A total of 2,165 subjects from the normal population
were randomly selected to take part in the SF-36 in this
Table 1 Demographic and clinical characteristics of patients
(n = 108)






Single, divorced, or widowed 26 24.1
Educational level
Elementary school and below 46 42.6
Junior and Senior high school 42 38.9








Treatment duration on interview
≤ 8 weeks 59 54.6
9–16 weeks 27 25.0
≥17 weeks 22 20.4
ALT level*
Mean (SD) 50.52 (50.01)
*ALT = alanine transaminase; SD = standard deviation.
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design from a target population of residents in one city
and four counties of Taiwan in 1994 [29], from the
same residential area as antiviral-treated CHC patients.
Individuals aged less than 27 years and more than
77 years were excluded for the sake of comparable distri-
butions of age and gender between the population norms,
and 256 of the population norms were frequency-matched
by age and gender.
The CLDQ, developed by Younossi et al. [12], has
been used in most recent studies of HRQOL in patients
with CLD. The questionnaire contains 29 items divided
into domains: abdominal symptoms (AB), activity (AC),
emotional function (EM), fatigue (FA), systemic symptoms
(SY), and worry (WO). Overall CLDQ scores calculated
for each domain range from 1 (most impaired) to 7, with
higher scores indicating a minimum frequency of symptoms
and hence a better HRQOL. The total score is calculated as
the average score of the 29 items. The original questionnaire
has good test-retest reliability (r = 0.90) and cross-sectional
validity [12]. The Chinese version in Taiwan was translated
using the forward and backward translation method in 2011
[30]. The resulting instrument was rated by content validity
index (CVI) for validity and Cronbach’s alpha and test-retest
reliability for reliability. The CVI value was 0.86 for each
item and the reliability coefficient of two tests for the
total scale was above 0.92 in this study. IRB approval
was obtained from the investigators’ affiliated universities,
as well as the hospital where patients were recruited. All
participants provided written informed consent after the
study purpose, procedures, and the right to withdraw had
been explained in detail.
Data analysis
Descriptive analysis was applied to all antiviral-treated
patients (n = 108) for baseline characteristics, the SF-36
questionnaire, and the CLDQ. One-way ANOVA was used
to estimate the differences between the 64 antiviral-treated
CHC patients, the 64 patients not undergoing antiviral
therapy, and the 256 Taiwanese population norms, includ-
ing the 8 domains and 2 component summary scales of
the SF-36. An independent t-test was used to estimate
the differences between antiviral-treated CHC patients
and CHC patients without antiviral therapy, including
the six domains of the CLDQ. Baseline characteristics
were chosen for independent variables to predict factors on
PCS, MCS, and the CLDQ via multiple linear regression.
Demographic items included age, gender, marital status,
education, current employment, monthly income, partici-
pants’ baseline clinical characteristics on interview (includ-
ing serum ALT levels), and treatment duration obtained
from medical records. Data analysis was conducted in SPSS
for Windows 12.0 (SPSS Inc., Chicago, IL), with two-sided
p < 0.05 set as statistical significance.Results
Baseline characteristics of 108 antiviral-treated CHC patients
Of the 108 enrolled patients, 59 (54.6%) were male. Age
ranged from 27 to 77 years, with an average age of
55.2 years. Over half of the patients (57.4%) had an edu-
cation level above junior high school, while 82 patients
(75.9%) were married and lived with their families. Most
patients (56.5%) were currently employed, though only
35.2% had a monthly income more than NT$30,000.
The mean ALT level was 50.52 U/L (SD = 50.01). Mean
treatment duration at patient interviews was 11.19 weeks
(SD = 7.78), while the treatment duration of 59 patients
(54.6%) ranged from 1 to 8 weeks (Table 1).
Quality of life in antiviral-treated CHC patients compared
with population norms and patients without antiviral therapy
In 108 recruits, the average score of ‘role physical’ was
lowest, with a score of 37.50 (SD = 44.36), while ‘phys-
ical functioning’ was highest, with a score of 78.33
(SD = 20.29). Three scales and two component summary
scales scored below 50: role physical, vitality (49.07,
SD = 22.87), role emotion (45.35, SD = 47.03), PCS (41.65,
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the population norms, the mean differences in the six
SF-36 domains, with the exception of PF and BP, were
significantly lower. The maximal reduction in scores for
patients was approximately 37.0 points below predicted
scores for norms on the role physical scale. CHC patients
undergoing antiviral treatment also scored significantly
lower on the two component summary scales compared
with general norm populations (p < 0.05). Compared with
CHC patients without antiviral therapy, significantly lower
scores on five scales, namely, RP, VT, RE, and MH of
SF-36, and PCS, were observed in antiviral-treated CHC
patients (p < 0.01), as shown in Table 2.
The mean CLDQ score of 108 patients was 5.27
(SD = 0.96). The two lowest scores out of the six 3CLDQ
subscales were ‘fatigue’ (average 4.66, SD = 1.34) and ‘sys-
temic symptoms’ (average 5.01, SD = 1.04), while the high-
est was ‘worry’ (average 5.97, SD = 1.12), indicating that
most patients had serious symptoms of fatigue, as well as
systemic symptoms such as itchy skin, dry mouth, muscle
cramps, and dyspnea (Table 3). Compared to patients
without antiviral therapy, significantly lower scores on
three scales, specifically, fatigue, systemic symptoms, and
emotional function, of the CLDQ, were noted in antiviral-
treated CHC patients (p < 0.05), as shown in Table 2.
Correlations between scores of SF-36 instruments and the
CLDQ for 108 antiviral-treated CHC patients
All SF-36 subscales correlated significantly with all
scores of CLDQ subscales (r > 0.20), ranging from weakTable 2 Scores of SF-36 between antiviral-treated CHC patien
antiviral therapy
SF-36 domains & CLDQ General populations
(N = 256,A) mean (SD)
CHC without antivi
patients (N = 64,B)
Physical functioning 82.79 (22.16) 71.95 (29.33
Role physical 72.95 (41.34) 66.07 (45.36
Bodily pain 74.26 (17.97) 80.63 (25.04
General health 64.78 (19.96) 41.84 (28.57
Vitality 65.33 (16.80) 60.94 (25.91
Social functioning 83.35 (15.98) 81.53 (22.49
Role emotional 79.43 (37.72) 78.11 (37.70
Mental health 70.91 (14.77) 71.88 (18.43
PCS 48.39 (8.52) 52.97 (17.20
MCS 49.73 (8.19) 49.73 (12.00






*p < 0.05, **p < 0.01; Age and gender were matched; SD: standard deviation; post-hto moderate, with the exception of the physical function-
ing scale of the SF-36 having no significant correlation
with the abdominal symptom domain of the CLDQ
(Table 3). The strongest association was between the
fatigue subscales of the CLDQ and all SF-36 scales,
followed by the associations between scales of systemic
symptoms and emotional function.
Predictors of total HQLQ for 108 antiviral-treated
CHC patients
Multiple linear regression analysis predicted the PCS,
MCS, and CLDQ scores. Table 4 shows beta coefficients
obtained from each independent variable and the R2 values
obtained from each regression model, which measures
the proportion of variance in the dependent variable
accounted for in the regression model. Significant pre-
dictors of PCS include treatment duration (9–16 weeks;
β = −9.38) and monthly income (greater than NT$30,000;
β = 8.47). Results for the PCS showed a significant positive
correlation with monthly income and a negative cor-
relation with treatment duration. Regression models
explained 28% of total variation in the PCS. The stan-
dardized regression coefficient showed that the monthly
income and 9–16 weeks treatment duration had the
greatest impact on PCS scores.
The significant predictor of the MCS was a monthly
income greater than NT$30,000 (β = 0.88). Results of the
MCS showed a significant positive correlation with the
patient’s monthly income. Regression models explained




(N = 64,C) Mean (SD)
F¸ (post-hoc multiple
comparison) t-test
) 75.86 (21.85) 6.57** (A > B)
) 35.94 (44.29) 19.19** (A > C&B > C)
) 73.30 (22.84) 2.88
) 51.78 (20.99) 32.35** (A > C > B)
) 50.00 (25.09) 15.01**(A,B > C)
) 75.23 (24.39) 4.78**(A > C)
) 43.20 (46.66) 22.32** (A,B > C)
) 61.00 (20.51) 10.10** (A,B > C)
) 40.78 (12.50) 20.06** (B > A > C)







oc multiple comparison by Scheffe’ method.
Table 3 Pearson’s correlation coefficients between CLDQ subscales and SF-36 domains (n = 108)
CLDQ Mean (SD) SF-36
Items PF RP BP GH VT SF RE MH PCS MCS
Abdominal symptoms 5.72 (1.30) 0.16 0.21* 0.39** 0.32** 0.26** 0.37** 0.31** 0.39** 0.21* 0.41**
Fatigue 4.66 (1.34) 0.46** 0.55** 0.57** 0.54** 0.77** 0.63** 0.55** 0.49** 0.52** 0.70**
Systemic symptoms 5.01 (1.04) 0.43** 0.47** 0.53** 0.36** 0.53** 0.56** 0.49** 0.44** 0.49** 0.52**
Activity 5.17 (1.56) 0.43** 0.47** 0.39** 0.33** 0.45** 0.45** 0.38** 0.31** 0.48** 0.38**
Emotional function 5.08 (1.36) 0.47** 0.51** 0.45** 0.53** 0.58** 0.59** 0.59** 0.74** 0.42** 0.75**
Worry 5.97 (1.12) 0.38** 0.30** 0.40** 0.41** 0.37** 0.44** 0.36** 0.48** 0.35** 0.48**
*p < 0.05; ** p< 0.01.
Chang et al. Health and Quality of Life Outcomes 2014, 12:97 Page 5 of 8
http://www.hqlo.com/content/12/1/97regression coefficient showed that monthly income had
the greatest impact on MCS scores.
Significant predictors of the CLDQ included gender
(male, β = 0.43) and monthly income greater than NT
$30,000 (β = 0.68). Regression models explained 16% of
the total variation in the CLDQ. The standardized re-
gression coefficient showed that the monthly income
and gender had the greatest impact on CLDQ scores.
Discussion
This study rated the effect of IFN-based treatment for
CHC patients on subjective function and well-being.
The key results indicated that antiviral-treated CHC
patients experienced a marked decrease in scores on 6
scales, as well as the PCS and MCS of the SF-36, ranging
from 3.4 (MCS) to 37.0 (RP) points below the scores of
the Taiwanese population norms. In 4 scales, as well as
the PCS of the SF-36, ranged from 3.4 (MCS) to 34.9
(RE) points below the scores of patients without antiviral
therapy. Assuming clinically meaningful differences of
3–5 points [31], the differences on all scales for CHC
patients with IFN-based treatment after adjusting for
age and gender were substantial, especially for scores on
the RP and RE scales. The strongest association between
questionnaires was between the fatigue subscale of the
CLDQ and the VT and SF scales of the SF-36. In
addition, we identified female gender, treatment durationTable 4 Multivariate linear regression** for predictive factors
Variables entered PCS
β(SE) P b
Treatment duration (<8 weeks as reference)
9–16 weeks −9.38(2.69) 0.00 −0
>17 weeks −3.83(2.88) 0.19 −0
Monthly income (≤NT$10,000 as reference)
>NT$30,000 8.47(3.54) 0.02 0.3
NT$10,001 ~ 30000 5.69(3.39) 0.10 0.1
Gender (female as reference) 4.39(2.44) 0.08 0.1
R2 0.28
β = regression coefficient, b = standardized regression coefficient, SE = standard erro
**Adjusted for age, gender, marital status, education, current employment, and seruat 9–16 weeks, and monthly income as significant factors
affecting the HRQOL.
It is well-known that the majority of HCV-infected
patients are asymptomatic seropositive during its natural
course; however, HCV itself may decrease the HRQOL
in the absence of advanced liver disease [32-34]. A sys-
tematic review by Spiegel et al. identified 15 studies that
compared HRQOL in compensated HCV-seropositive
patients versus healthy controls without HCV, revealing
decreased weighted mean SF-36 scores including 7.0 (PF),
15.8 (RP), 12.8 in MCS, and 9.11 in PCS [34]. More recent
studies reported that CHC patients’ HRQOL was worse
than non-CHC patients, with CHC patients showing
significantly lower SF-36 scores in six domains, especially
in the VT, GH, and RP scales [22,23,35]. In the present
study, CHC patients undergoing antiviral therapy showed
significantly lower scores on five scales, namely, RP, VT,
RE, and MH of SF-36, and PCS, demonstrating a reduc-
tion in their HRQOL compared with patients without
antiviral therapy. The results reflect similar findings from
studies comparing HRQOL at baseline and after antiviral
treatment in CHC patients with IFN alone or with RBV in
addition [11,35,36]. The negative effect of antiviral therapy
on RP for CHC patients in this study was 27.7, worse
for those without antiviral therapy (ranging from −6.0
to −11.6) [22,23,35], while the negative effect on RE was
34.9 points, also much higher than the impact on CHCon PCS, MCS, and CLDQ (n = 108)
MCS CLDQ
β(SE) P b β(SE) P b
.33 0.66(2.81) 0.82 0.02 −0.32(0.22) 0.16 −0.15
.13 1.56(3.00) 0.60 0.05 0.09(0.24) 0.72 0.04
3 8.79(3.69) 0.02 0.35 0.68(0.29) 0.02 0.34
9 7.13(3.54) 0.05 0.24 0.37(0.28) 0.19 0.16
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to −18.1) [22,23,35].
The average CLDQ score of the 108 antiviral-treated
patients was 5.23 in this study, indicating a moderate
reduction in quality of life among antiviral-treated CHC
patients and it is a lower score than that of chronic
hepatitis patients treated with IFN-α in Tehran, Iran
(5.40) [37], and much lower than norms in the USA
(5.9) [38]. Compared to CHC patients without antiviral
therapy, antiviral-treated CHC patients demonstrated
significantly lower scores on three scales, namely, fatigue,
systemic symptoms, and emotional function, in the CLDQ.
Reductions in the HRQOL of CHC patients with antiviral
therapy were higher in magnitude than that reported
for CHC patients without antiviral therapy [20,39,40],
indicating that antiviral therapy has a severe impact on
CHC patients.
Significant correlations between scores on CLDQ sub-
scales and SF-36 scales were observed. The magnitude of
correlations between the fatigue subscale of the CLDQ
and SF-36 scales was higher, indicating that fatigue is the
most important factor explaining variations in functioning
and well-being in CHC patients undergoing antiviral treat-
ment. The highest correlations were between the CLDQ
subscale of fatigue and the SF-36 scale of vitality, and
the CLDQ subscale of emotional function and the SF-
36 mental health scale, which concurred with previous
reports [41,42]. This pattern of correlations between
the CLDQ and SF-36 subscales provides further evidence
for the convergent and discriminant validity of the CLDQ,
also indicated by Hauser et al. [43], Ferrer et al. [44], and
Younossi [38].
This study showed low PCS and MCS scores, especially
during treatment weeks 9–16. The lowest PCS score
(35.06) was comparable to one report from France dem-
onstrating progressive decreases in PCS and MCS scores
from treatment week 12 (PCS score 36.0, MCS score 41.6)
up to month 12 [11]. Similarly, Kang et al. reported the
lowest SF-36 scores in all domains at treatment week
12, while scores progressively increased thereafter [35].
This study failed to find a correlation between ALT
levels and the patients’ HRQOL, reflecting studies in
western countries finding no association between QOL
and serum ALT levels [24,34]. Among the demographic
variables examined, this study found that a patient’s
monthly income was the major predictor of PCS, MCS,
and CLDQ scores. This is consistent with previous findings
that self-perceived financial stress is the most influential
factor [24] and is compatible with research by Bezemer
et al. showing correlations between a patient’s income
(Euros) and PCS score [16]. This study illustrated that
patients with higher incomes have a significantly better
QOL during treatment compared to those with lower
incomes. While there were no significant differences inother variables except gender on the CLDQ, females
experienced a negative impact on their QOL, reflecting
findings by Bezemer et al. [16]. This study’s results indi-
cate that a patient’s gender (female), treatment duration
(mainly after week 8 and especially during weeks 9–16),
and monthly income are predictive factors of the patients’
QOL. This acknowledgement could help healthcare per-
sonnel understand a patient’s HRQOL during treatment
and guide nurses in providing better management of
patient discomfort based on different impacting factors.
For example, healthcare providers may offer CHC patients
adequate antiviral treatment information before treatment
week 8 and help patients apply for financial support from
available resources, especially for patients who need ex-
tended therapy. In addition, case-management can benefit
CHC patients through timely assessment of QOL using
both generic and disease-specific questionnaires, which
they can consult to determine how to relieve side effects
caused by treatment without delay. Furthermore, there is
a need to establish diverse programs that can help patients
improve their HRQOL through a continuous education
curriculum, which also provides nurses with adequate
knowledge and skills to achieve best practice in managing
patients’ physical and emotional changes during antiviral
treatment.
Conclusion
Our study showed a decrease in the QOL of Taiwanese
antiviral-treated CHC patients compared with Taiwanese
population norms. The results showed that treatment
had a particularly serious negative impact on low income
earners, during weeks 9–16 of treatment, and an overall
greater effect on female subjects. The findings indicate a
need for updated counseling and educational materials
designed to provide adequate nursing management and
consistent healthcare service to this patient setting. Active
assessment and timely healthcare interventions could
improve the standard consultation programs as well as
patient’s quality of life.
This study was performed at one teaching hospital in
central Taiwan; therefore, the results may not be repre-
sentative of all CHC patients in Taiwan. A limitation of
the study was the small sample size, as we only recruited
64 age- and gender-matched CHC patients without anti-
viral therapy as an additional control group. We are cur-
rently performing a longitudinal follow-up study that
includes HRQOL measurements and analysis of biochem-
ical parameters for antiviral-treated CHC patients at base-
line, during-treatment, and post-treatment. Collaboration
with more hospitals and recruitment of more antiviral-
treated CHC patients would provide more comprehensive
data on patients’ HRQOL. Enhanced awareness and un-
derstanding of patients’ needs will ensure better healthcare
for antiviral-treated CHC patients in Taiwan.
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